APS-1/APECED患者的临床诊疗路径
本文通过5例病例阐述自身免疫性多内分泌综合征1型(APS-1)的扩展临床谱、新遗传机制、诊断挑战及新兴治疗。强调非内分泌表现常先于经典内分泌病出现,内分泌科医生在早期识别中起核心作用,并指出需考虑深内含子及显性负性AIRE变异,以及JAK抑制等靶向治疗前景。
要点
- APS-1常以慢性黏膜皮肤念珠菌病及多器官自身免疫为特征,非内分泌表现可先于内分泌病出现。
- 标准基因检测可能漏诊深内含子及显性负性AIRE变异,需扩展临床标准并提高警惕。
- APS-1为干扰素-γ驱动疾病,JAK抑制(如ruxolitinib)等靶向免疫调节治疗提供新方向。
核心结论
- APS-1/APECED是一种由AIRE基因双等位基因致病变异引起的单基因中枢免疫耐受障碍,经典呈常染色体隐性遗传。
- 非内分泌特征如自身免疫性肠炎、APECED皮疹、釉质发育不全、自身免疫性肺炎和肝炎常先于经典内分泌病出现,导致诊断延迟。
- 内分泌科医生常为首诊专科之一,在早期识别和长期管理中起核心作用;早期诊断可实现主动监测并及时启动疾病修饰治疗。
研究设计与样本
- 本文为临床综述/病例系列,呈现5例APS-1病例以说明其扩展临床谱、新遗传机制、关键诊断挑战和新兴治疗方法。
- 原文未报告样本量、检索范围等研究设计细节。
主要发现
- 5例病例展示了APS-1的扩展临床谱,包括非内分泌表现先于经典内分泌病出现。
- 诊断挑战包括标准基因检测的局限性,需考虑深内含子及显性负性AIRE变异。
- 机制研究确立APS-1为干扰素-γ驱动疾病,为JAK抑制(如ruxolitinib)等靶向免疫调节治疗提供依据。
关键数值与推荐
- 原文未报告具体诊断标准、数值阈值或推荐条款。
临床怎么用
- 内分泌科医生应提高对APS-1非内分泌表现的认识,以便早期识别和诊断。
- 对疑似APS-1患者,应扩展临床标准并注意标准基因检测的局限性,必要时考虑深内含子及显性负性AIRE变异。
- 早期诊断后应进行主动监测,并可能及时启动疾病修饰治疗如JAK抑制。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autoimmune polyendocrine syndrome type 1 (APS-1), also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a monogenic disorder of impaired central immune tolerance classically inherited in an autosomal recessive manner and caused by biallelic deleterious variants in the autoimmune regulator (AIRE) gene, leading to chronic mucocutaneous candidiasis and multiorgan autoimmunity. Although hypoparathyroidism and adrenal insufficiency are among the most common and clinically consequential manifestations, it is increasingly recognized that several non-endocrine features-including autoimmune enteritis, urticarial eruption (termed APECED rash), enamel hypoplasia, autoimmune pneumonitis, and autoimmune hepatitis-often precede classical endocrinopathies, contributing to delayed diagnosis. Endocrinologists are often among the first specialists to encounter these patients and play a central role in early recognition and longitudinal care. Here, we present 5 cases that illustrate the expanding clinical spectrum of APS-1, novel genetic mechanisms, key diagnostic challenges, and emerging therapeutic approaches. These cases highlight the importance of applying expanded clinical criteria and recognizing the limitations of standard genetic testing, including the need to consider deep intronic and dominant-negative AIRE variants. Finally, evolving mechanistic insights have established APS-1 as an interferon-γ-driven disease, providing a rationale for emerging targeted immunomodulatory therapies such as Janus kinase inhibition with ruxolitinib. Early diagnosis enables proactive surveillance and may allow timely initiation of disease-modifying treatment.
引用
- Webb T, Pechacek J, Lionakis MS, et al. Approach to the patient with APS-1/APECED. J Clin Endocrinol Metab. 2026. PMID: 42460781. doi:10.1210/clinem/dgag282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。